Sales & Marketing News | pharmaphorum

News

Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity therapies.

News

A new FTC report claims that pharmacy benefit managers generated $7.3bn by marking up specialty generics used to treat diseases like cancer and HIV.

News

FDA has started its review of an autoinjector version of Eisai and Biogen's Alzheimer's drug Leqembi that could allow patients to be dosed at home.

News

Johnson & Johnson has agreed to take over Intra-Cellular Therapies and its potential depression blockbuster Caplyta in a deal worth up to $14.6bn.

News

Biogen has offered to buy all the shares in Sage Therapeutics that it doesn't already own, taking control of their novel antidepressant Zurzuvae.

News

The UK's system of disclosing payments from pharma to healthcare professionals has gaps that hide potential conflicts of interest, claims study.